Hand, Foot And Mouth Disease – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Hand, Foot And Mouth Disease – Pipeline Review, H2 2016’, provides an overview of the Hand, Foot And Mouth Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hand, Foot And Mouth Disease , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hand, Foot And Mouth Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hand, Foot And Mouth Disease

The report reviews pipeline therapeutics for Hand, Foot And Mouth Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hand, Foot And Mouth Disease therapeutics and enlists all their major and minor projects

The report assesses Hand, Foot And Mouth Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hand, Foot And Mouth Disease

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hand, Foot And Mouth Disease

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hand, Foot And Mouth Disease pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

CJ HealthCare Corp

Sentinext Therapeutics Sdn Bhd

Takeda Pharmaceutical Company Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Hand, Foot and Mouth Disease Overview 6

Therapeutics Development 7

Pipeline Products for Hand, Foot and Mouth Disease - Overview 7

Pipeline Products for Hand, Foot and Mouth Disease - Comparative Analysis 8

Hand, Foot and Mouth Disease - Therapeutics under Development by Companies 9

Hand, Foot and Mouth Disease - Therapeutics under Investigation by Universities/Institutes 10

Hand, Foot and Mouth Disease - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Hand, Foot and Mouth Disease - Products under Development by Companies 13

Hand, Foot and Mouth Disease - Products under Investigation by Universities/Institutes 14

Hand, Foot and Mouth Disease - Companies Involved in Therapeutics Development 15

CJ HealthCare Corp 15

Sentinext Therapeutics Sdn Bhd 16

Takeda Pharmaceutical Company Ltd 17

Hand, Foot and Mouth Disease - Therapeutics Assessment 18

Assessment by Monotherapy Products 18

Assessment by Combination Products 19

Assessment by Target 20

Assessment by Mechanism of Action 21

Assessment by Route of Administration 22

Assessment by Molecule Type 23

Drug Profiles 25

(coxsackievirus [serotype A16] + enterovirus [serotype 71]) vaccine - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

CJ-40010 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

D-5 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

DC-07090 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Enterovirus [serotype EV-A71] (virus like particle, bivalent) vaccine - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

hand, foot and mouth disease (viral like particle, bivalent) vaccine - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Small Molecules to Inhibit MAP2K1 for Hand, Foot and Mouth Disease - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

TAK-021 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Hand, Foot and Mouth Disease - Dormant Projects 33

Hand, Foot and Mouth Disease - Product Development Milestones 34

Featured News & Press Releases 34

Mar 11, 2012: Inviragen Reports Top-Line Results From Phase I Trial Of INV21 Vaccine For Treatment Of Hand, Foot And Mouth Disease 34

Appendix 35

Methodology 35

Coverage 35

Secondary Research 35

Primary Research 35

Expert Panel Validation 35

Contact Us 35

Disclaimer 36

List of Tables

List of Tables

Number of Products under Development for Hand, Foot and Mouth Disease, H2 2016 7

Number of Products under Development for Hand, Foot and Mouth Disease – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Hand, Foot and Mouth Disease – Pipeline by CJ HealthCare Corp, H2 2016 15

Hand, Foot and Mouth Disease – Pipeline by Sentinext Therapeutics Sdn Bhd, H2 2016 16

Hand, Foot and Mouth Disease – Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 17

Assessment by Monotherapy Products, H2 2016 18

Assessment by Combination Products, H2 2016 19

Number of Products by Stage and Target, H2 2016 20

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 24

Hand, Foot and Mouth Disease – Dormant Projects, H2 2016 33

List of Figures

List of Figures

Number of Products under Development for Hand, Foot and Mouth Disease, H2 2016 7

Number of Products under Development for Hand, Foot and Mouth Disease – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 18

Number of Products by Molecule Types, H2 2016 23

Number of Products by Stage and Molecule Types, H2 2016 23

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports